kabutan

Carna Biosciences, Inc.(4572) Summary

4572
TSE Growth
Carna Biosciences, Inc.
371
JPY
-13
(-3.39%)
Dec 12, 3:30 pm JST
2.38
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
353.5
Dec 12, 11:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
8.22
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:06 am
360 JPY 2.31 USD
Previous Close Dec 11
384 JPY 2.46 USD
High Dec 12, 9:29 am
464 JPY 2.98 USD
Low Dec 12, 10:40 am
345 JPY 2.21 USD
Volume
7,062,800
Trading Value
2.89B JPY 0.02B USD
VWAP
409.26 JPY 2.63 USD
Minimum Trading Value
37,100 JPY 238 USD
Market Cap
7.10B JPY 0.05B USD
Number of Trades
10,992
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
239
1-Year High Dec 12, 2025
10,992
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 1,585,800
Nov 28, 2025 0 1,471,300
Nov 21, 2025 0 1,518,200
Nov 14, 2025 0 1,548,500
Nov 7, 2025 2,500 1,580,900 632.36
Company Profile
Carna Biosciences, Inc. specializes in drug discovery support services, primarily focusing on the production and sale of kinase proteins and analysis outsourcing. The company is also expanding into drug discovery.
Sector
Pharmaceuticals
Carna Biosciences, Inc. offers a diverse range of products and services supporting early-stage drug discovery, including the manufacture and sale of kinase proteins, assay development, profiling and screening services, and cell-based assay services. The company's strength lies in its extensive lineup of kinase proteins and assay kits. Additionally, Carna Biosciences is focusing on in-house drug discovery with kinase inhibitors, advancing research and development of new drugs in key disease areas such as cancer and immune-inflammatory disorders. For cancer-related projects, the company plans to conduct studies up to Phase II trials at most, while for other diseases, it aims to carry out Phase I trials or preclinical studies before out-licensing to pharmaceutical companies.